Search for: All records

Abstract The brain has long been conceptualized as a network of neurons connected by synapses. However, attempts to describe the connectome using established network science models have yielded conflicting outcomes, leaving the architecture of neural networks unresolved. Here, by performing a comparative analysis of eight experimentally mapped connectomes, we find that their degree distributions cannot be captured by the well-established random or scale-free models. Instead, the node degrees and strengths are well approximated by lognormal distributions, although these lack a mechanistic explanation in the context of the brain. By acknowledging the physical network nature of the brain, we show that neuron size is governed by a multiplicative process, which allows us to analytically derive the lognormal nature of the neuron length distribution. Our framework not only predicts the degree and strength distributions across each of the eight connectomes, but also yields a series of novel and empirically falsifiable relationships between different neuron characteristics. The resulting multiplicative network represents a novel architecture for network science, whose distinctive quantitative features bridge critical gaps between neural structure and function, with implications for brain dynamics, robustness, and synchronization. 

Identifying novel drug-target interactions is a critical and rate-limiting step in drug discovery. While deep learning models have been proposed to accelerate the identification process, here we show that state-of-the-art models fail to generalize to novel (i.e., never-before-seen) structures. We unveil the mechanisms responsible for this shortcoming, demonstrating how models rely on shortcuts that leverage the topology of the protein-ligand bipartite network, rather than learning the node features. Here we introduce AI-Bind, a pipeline that combines network-based sampling strategies with unsupervised pre-training to improve binding predictions for novel proteins and ligands. We validate AI-Bind predictions via docking simulations and comparison with recent experimental evidence, and step up the process of interpreting machine learning prediction of protein-ligand binding by identifying potential active binding sites on the amino acid sequence. AI-Bind is a high-throughput approach to identify drug-target combinations with the potential of becoming a powerful tool in drug discovery.